News articles about TearLab Corporation (NASDAQ:TEAR) (TSE:TLB) have been trending somewhat positive on Sunday, according to Accern Sentiment Analysis. The research group ranks the sentiment of press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. TearLab Corporation earned a coverage optimism score of 0.06 on Accern’s scale. Accern also assigned news headlines about the medical research company an impact score of 46.2243393870427 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Shares of TearLab Corporation (NASDAQ TEAR) opened at 1.38 on Friday. The company’s market capitalization is $7.92 million. The stock’s 50 day moving average price is $1.73 and its 200-day moving average price is $2.23. TearLab Corporation has a 52-week low of $1.20 and a 52-week high of $7.70.
TearLab Corporation (NASDAQ:TEAR) (TSE:TLB) last issued its quarterly earnings data on Monday, August 14th. The medical research company reported ($0.68) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.75) by $0.07. The business had revenue of $7.00 million for the quarter, compared to analysts’ expectations of $6.86 million. The business’s quarterly revenue was up 1.4% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.08) earnings per share. On average, equities analysts expect that TearLab Corporation will post ($2.76) earnings per share for the current year.
Several research firms recently issued reports on TEAR. Zacks Investment Research downgraded TearLab Corporation from a “buy” rating to a “hold” rating in a research note on Wednesday, August 30th. HC Wainwright reiterated a “buy” rating and set a $4.00 target price on shares of TearLab Corporation in a research report on Tuesday, August 15th. Five equities research analysts have rated the stock with a buy rating, The stock presently has a consensus rating of “Buy” and an average target price of $4.90.
COPYRIGHT VIOLATION NOTICE: “TearLab Corporation (TEAR) Earns Daily News Sentiment Score of 0.06” was first reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of United States and international trademark & copyright laws. The legal version of this article can be read at https://ledgergazette.com/2017/09/17/tearlab-corporation-tear-getting-somewhat-positive-news-coverage-analysis-shows.html.
TearLab Corporation Company Profile
TearLab Corporation is an in-vitro diagnostic company. The Company has commercialized a tear testing platform, the TearLab Osmolarity System, which enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. The Company, through its subsidiary TearLab Research, Inc, develops technologies to enable eye care practitioners to test a range of biomarkers (chemistries, metabolites, genes and proteins) at the point-of-care.
Receive News & Ratings for TearLab Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TearLab Corporation and related companies with MarketBeat.com's FREE daily email newsletter.